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Abstract
Cancer-associated fibroblasts are essential modifiers of the tumor microenvironment. The collagen-binding integrin
α11β1 has been proposed to be upregulated in a pro-tumorigenic subtype of cancer-associated fibroblasts. Here,
we analyzed the expression and clinical relevance of integrin α11β1 in a large breast cancer series using a novel
antibody against the human integrin α11 chain. Several novel monoclonal antibodies against the integrin α11 sub-
unit were tested for use on formalin-fixed paraffin-embedded tissues, and Ab 210F4B6A4 was eventually selected
to investigate the immunohistochemical expression in 392 breast cancers using whole sections. mRNA data from
METABRIC and co-expression patterns of integrin α11 in relation to αSMA and cytokeratin-14 were also investi-
gated. Integrin α11 was expressed to varying degrees in spindle-shaped cells in the stroma of 99% of invasive
breast carcinomas. Integrin α11 co-localized with αSMA in stromal cells, and with αSMA and cytokeratin-14 in
breast myoepithelium. High stromal integrin α11 expression (66% of cases) was associated with aggressive breast
cancer features such as high histologic grade, increased tumor cell proliferation, ER negativity, HER2 positivity, and
triple-negative phenotype, but was not associated with breast cancer specific survival at protein or mRNA levels. In
conclusion, high stromal integrin α11 expression was associated with aggressive breast cancer phenotypes.
Keywords: integrin α11β1; monoclonal antibody; breast cancer; cancer associated fibroblasts; myoepithelial cells; clinico-pathologic
features
Received 13 June 2019; Revised 5 September 2019; Accepted 16 September 2019
Conflict of interest statement: HYHS, RKR, DG and LAA are named as inventors on a patent regarding the 210F4B6A4 monoclonal antibody, filed by the University
of Bergen, Norway.
Introduction
Breast cancer is a heterogeneous disease developed
from genetically altered mammary epithelial cells, and
there is a complex interplay between tumor cells and
the surrounding tumor microenvironment (TME). The
TME consists of various stromal cells, the extracellular
matrix (ECM) scaffold, and the interstitial fluid, and
both cellular and noncellular components have been
shown to play an active role in tumor development,
progression and metastasis [1]. Features of the TME
contribute to clinically relevant variations in breast
cancer phenotypes and have also been shown to pre-
dict patient outcome [2,3].
Integrins are transmembrane cell-surface receptors
crucial for bidirectional communication between cells
and the surrounding ECM [4]. The collagen receptor
integrin α11β1 has emerged as a potentially important
marker which is upregulated in fibroblasts during their
differentiation into an activated phenotype [5–7]. Acti-
vated fibroblasts in the TME, termed cancer-associated
fibroblasts (CAFs), constitute an abundant stromal cell
type, especially in tumors with high stromal content
such as pancreatic and breast carcinomas [1,8].
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Accumulating data suggest the existence of diverse
CAF subtypes, which differ in their biological func-
tions, source of origin and expression of various
markers [9–14]. Different fibroblasts may vary in their
proliferative, secretory and contractile abilities and,
most importantly, their influence on tumor growth and
progression [9–14].
Integrin α11β1 contributes to fibroblast function in
wound healing, fibrosis and in different tumor models
(reviewed in Zeltz and Gullberg [5]), binds to fibrillar
collagen [15], and has been linked to collagen reorga-
nization [5,15] and tumor interstitial fluid pressure
[16,17]. In vivo, stromal integrin α11-deficiency
reduced the growth of triple-negative breast cancer
[16] and prostate cancer xenografts [18], and reduced
primary tumor growth [19,20] and metastasis [20] in
lung cancer xenografts models. Thus, integrin α11β1
could potentially represent a novel marker for a tumor-
supportive subtype of CAFs and thereby play an
important role in breast cancer progression.
The lack of reliable anti-human integrin α11 anti-
bodies has limited the investigation of integrin α11 in
retrospective studies using formalin-fixed and paraffin-
embedded (FFPE) tumor material. We here present for
the first time a study of integrin α11 expression in a
large human breast cancer cohort with long-term
follow-up, using a new in-house antibody specific for
the human integrin α11 chain, aiming to investigate
the expression of integrin α11 in human breast cancer,
associations with aggressive phenotypes, as well as
potential prognostic impact.
Materials and methods
Anti-human integrin α11 antibodies
Mouse monoclonal antibodies reactive to the extracel-
lular domain of the integrin α11 subunit were gener-
ated by NanoTools (Teningen, Germany) for CCBIO
(Centre of Cancer Biomarkers, University of Bergen,
Bergen, Norway) as described in [21] and conducted
in accordance with the German Animal Welfare Act
and approved by the local German Authorities
(RP Freiburg, AZ35/9185.82/I-13/03). In brief, mice
were immunized with soluble human integrin α11β1.
Primary hybridoma screening was performed as
described in [21]. In brief, selected hybridomas were
reactive to C2C12-α11 cells, but not to C2C12,
C2C12-α2 cells or A431 (expressing integrin β1 and a
variety of integrin α chains such as α2, α3, and α5,
but not integrin α11 [22]). Secondary hybridoma
screening was performed with flow cytometry and
western blotting as described elsewhere [23]. Anti-
integrin α11 antibodies were then tested on FFPE
tissue.
Mouse monoclonal antibodies reactive to the cyto-
plasmic domain of integrin α11 subunit were gener-
ated using the peptide H-CRREPGLDPTPKVLE-OH
by Oslo University Hospital (Oslo, Norway). The pep-
tide was custom-synthesized and conjugated to key-
hole limpet hemocyanin (KLH) (Mimotopes, Clayton,
Australia). BALB/c mice were immunized with the
peptide-KLH conjugate and hybridomas constructed
by fusion of splenocytes with the NS0 myeloma cell
line (approved by the Norwegian Food Safety Author-
ity with permit number 7903). Primary hybridoma
screening was performed using antibody capture
assays with biotinylated peptide (Biotin-SGSGRREP
GLDPTPKVLE-OH) presented on streptavidin-coated
96-well microplates (Wallac Oy, Turku, Finland).
Secondary screening was undertaken by western blot-
ting and immunostaining of integrin α11-positive and
-negative cell lines and also frozen sections of pan-
creatic ductal adenocarcinoma (PDAC). D120.4 was
then selected for use on FFPE tissue.
Monoclonal antibodies were purified from hybridoma
culture supernatants by protein-A chromatography.
Cell culture
The integrin α11- or α2- overexpressing C2C12 cell
lines, C2C12-α11, or C2C12-α2, were prepared as
described previously [15], while U2OS and HEK293
were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). All cells
were cultured in DMEM with Glutamax (Gibco,
Gaithersburg, MD, USA) supplemented with 10%
fetal bovine serum, 100 units/ml of penicillin and
0.1 mg/ml of streptomycin (all from GE Healthcare,
Chicago, IL, USA) under standard culture conditions
(5% CO2, 37 C).
Western blotting and RT-qPCR
The cells were cultured to subconfluence and washed
with PBS, lysed and collected in RIPA buffer
(150 mM NaCl, 50 mM Tris base, 0.1% sodium dode-
cyl sulfate, 12 mM deoxycholate, 1% Nonidet-P40, 1%
Triton X-100, pH 8) and supplemented with protease
inhibitors (Roche Diagnostics, Basel, Switzerland).
Protein concentration was determined by BCA assay
(Bio-Rad, Hercules, CA, USA) after centrifugation. Of
cleared lysates, 20 μg were analyzed by SDS-PAGE
and blotted onto PVDF membranes (Millipore, Bur-
lington, MA, USA). The antibodies used were as
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follows: mouse anti-human monoclonal integrin α11
antibody 210F4B6A4 (custom-made by NanoTools for
CCBIO) (2.9 μg/ml), mouse anti-human monoclonal
integrin α11 antibody D120.4 (custom-made by Oslo
University Hospital) (2.8 μg/ml), rabbit anti-human
polyclonal integrin α11 antibody [24] (1,9 μg/ml),
anti-β-actin (Sigma–Aldrich, Steinheim, Germany)
(1:5000), in addition to goat anti-rabbit and goat
anti-mouse HRP-conjugated antibodies (Santa Cruz
Biotechnology, Dallas, TX, USA) (1:5000). Chemilu-
minescence signals were developed using the ECL
Western-blotting systems kit (GE Healthcare) and
photographed using the ChemiDoc XRS device and
the Quantity One 1-D Analysis Software (Bio-Rad).
RT-qPCR was performed as previously described
[6]. In brief, total RNA was prepared from the cells
using RNeasy Mini Kit (Qiagen, Hilden, Germany),
and 1 μg RNA was used for reverse transcription to
cDNA using iScript Reverse Transcription Supermix
(Bio-Rad). qPCR mixtures were prepared with 20 ng
of reverse-transcribed cDNA as a template, along with
0.5 μM of each primer, in a 10 μl qPCR using iQ
SYBR Green Supermix (Bio-Rad). The qPCR was
performed in a LightCycler 480 Instrument II (Roche
Diagnostics). The reactions were prepared in triplicate
for individual cDNA sample along with the negative
controls where no cDNA was added for each primer
pair. The experiment was repeated three times. The
primers used were for target gene ITGA11 and two ref-
erences genes 18S rRNA and β-actin, and their
sequences are shown in Table 1.
FFPE cell pellets
The cell lines were collected at subconfluence, cen-
trifuged and washed with PBS. Plasma (Octaplas,
Haukeland University Hospital, Bergen, Norway) and
thrombin (Merck, Darmstadt, Germany) were added
sequentially, and the pellets were fixed in 4% formal-
dehyde for 24 h and transferred to ethanol/xylene prior
to embedding in paraffin wax.
Pancreatic ductal adenocarcinomas
Expression of the integrin α11 chain was investigated
in corresponding cryosections and FFPE sections from
five different PDACs from a research biobank
(Regional Ethical Committee approval 2013/1772) col-
lected at Haukeland University Hospital [25].
Breast cancer series
Integrin α11 expression was investigated in a
population-based cohort of 534 women diagnosed with
primary invasive breast carcinoma (aged 50–69 at
diagnosis) during 1996–2003 who resided in
Hordaland County in Norway, as described previously
[26]; treatment was given according to standard
national guidelines at the time. Patients with distant
metastatic disease at diagnosis were not included.
Also, 14 cases were not included because of insuffi-
cient tissue in remaining blocks, leaving 520 cases for
initial inclusion. Follow-up data were provided by the
Norwegian Cause of Death Registry. Median follow-
up time of survivors was 216 months (range
166–256), and last follow-up date was 30 June 2017.
The study was approved by the Regional Committee
for Medical and Health Sciences Research Ethics
(REK #2014/1984), and was performed in accordance
with the Declaration of Helsinki. In accordance with
national ethics guidelines and procedures for such ret-
rospective studies, all participants were contacted with
written information on the study and asked to respond
if they objected.
Immunohistochemistry
Cryosections of PDACs (4–5 μm) were fixed in ace-
tone, rehydrated with PBS, and endogenous peroxi-
dase activity was blocked with peroxidase block
(Dako, K4007, Agilent, Santa Clara, CA, USA). Anti-
integrin α11 210F4B6A4 (0.39 μg/ml) was incubated
in a humidity chamber overnight (4 C), followed by
HRP-labeled anti-mouse antibody (Dako, K4001)
(30 min), diaminobenzidine (DAB) (5 min) and hema-
toxylin (Dako, S2020) (3 min). A polyclonal antibody
[24] and the new monoclonal antibody 203E3, recently
demonstrated to be suitable for immunostaining of
cryosections [21], were used as controls.
Immunohistochemical staining of FFPE tumor tissue
was done on whole tissue sections (4–5 μm) mounted
on poly-lysine coated glasses. The sections were baked
Table 1. Primer sequences for qPCR
Gene symbol Forward primer Reverse primer Amplicon size (bp)
ITGA11 50-CACGACATCAGTGGCAATAAG 50-GACCCTTCCCAGGTTGAGTT 132
18S rRNA 50-GCAATTATTCCCCATGAACG 50-GGGACTTAATCAACGCAAGC 68
ACTB 50-GTGTGATGGTGGGAATGGGT 50-TCTGGGTCATCATTTCACGGTTGG 240
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at 56 C for 48 h followed by cooling to room temper-
ature (RT) (20 min), dewaxed with xylene/ethanol,
and antigen retrieval was performed in Target
Retrieval Solution pH 9 (Dako, K8010) (120 C,
10 min) in a pressure cooker (Decloaking Chamber
Plus, Biocare Medical, Pacheco, CA, USA). Staining
was performed using a Dako autostainer Plus (Dako)
with EnVision FLEX+ kit (Dako, K801021-2). Peroxi-
dase Block was applied for 8 min, followed by incuba-
tion with anti-integrin α11 210F4B6A4 (0.29 μg/ml)
(1 h RT), FLEX+ Mouse Linker (Dako, K8022)
(15 min), FLEX+ HRP (20 min), DAB (5 min) and
hematoxylin (3 min). Integrin α11-positive and
integrin α11-negative FFPE cell pellets in addition to
serial sections from one invasive breast carcinoma
were used as biological controls. An anti-human
IgG2b antibody was used as isotype control. Positive
and negative controls were included in each run.
Efforts were made to reduce the loss of tissue, such as
baking prior to the IHC protocol, and using freshly cut
sections and poly-lysine coated glasses.
For double and triple immunohistochemical staining,
deparaffinization/rehydration and antigen retrieval were
done as described above. Triple staining with antibodies
against integrin α11, αSMA and factor VIII (FVIII)
was done on 20 FFPE invasive breast carcinomas with
Ventana autostainer (Discovery Ultra, Ventana Medical
systems, Tuscon, AZ, USA). After peroxidase block
(Roche Diagnostics, 760–4840) (8 min), the sections
were incubated with anti-integrin α11 210F4B6A4
(0.29 μg/ml) (1 h RT), Omnimap anti-mouse HRP
(Roche Diagnostics, 760–4310) (16 min) and amplifica-
tion with Amp HQ kit (Roche Diagnostics, 760–052)
(20 min) and anti-HQ HRP (Roche Diagnostics,
760–4602) (16 min) following visualization with teal
(Roche Diagnostics, 760–247) (32 + 16 min). The sec-
tions were denaturated in CC2 (Ventana, 950–243)
(8 min 100 C), and incubated with anti-αSMA (Dako,
M0851) (1:100, 36 C 32 min), Ultramap-anti mouse
AP (Roche Diagnostics, 760–4312) (16 min) and
visualized with yellow (Roche Diagnostics, 760–239)
(44 min). After another denaturation with reaction
buffer (Ventana, 95–300) (95 C 20 min), the sec-
tions were incubated with anti-FVIII (Dako, A0088)
(1:1600, 1 h RT), Ultramap anti-rabbit HRP (Roche
Diagnostics, 760–4315) (12 min) and then purple
(Roche Diagnostics, 760–229) (20 min).
Double immunofluorescent staining with antibodies
against integrin α11 and cytokeratin-14 (CK14) was
done on 15 FFPE invasive breast carcinomas. After
antigen retrieval, the sections were incubated with
PBS/1% BSA/0.1% TritonX-100, followed by anti-
human integrin α11 210F4B6A4 (1.5 μg/ml) in
combination with anti-CK14 (Abcam, Cambridge,
United Kingdom, 119695) (1:700) (1 h RT), and then
Alexa Fluor® 594 goat anti-mouse IgG (AffiniPure,
Jackson ImmunoResearch, West Grove, PA, USA,
115-585-062) (1:700) and Alexa Fluor® 488 goat anti-
rabbit IgG (AffiniPure, 111-545-045) (1:700) (1 h
RT). Mounting was done with ProLong™ Gold Anti-
fade Mountant with DAPI (ThermoFisher, Waltham,
MA, USA, P36931) and results recorded using a Zeiss
Axioscope microscope equipped with Colibri 7 light
source, AxioCam 503 mono camera and Axiovision
software.
Evaluation of staining
Breast cancer sections were examined blinded for
patient characteristics and outcome by a senior breast
cancer pathologist, LAA, and HYHS. Of 520 stained
sections, 128 tumors were excluded from evaluation
because of inadequate tissue remaining after the anti-
gen retrieval procedure. Altogether 392 cases were
evaluated for integrin α11-positive staining by a
staining index (SI) score (0–9) which was obtained by
multiplying the score for intensity of staining (0 =
absent, 1 = weak, 2 = moderate, or 3 = strong) by the
score for percentage of fibrous stroma stained
(<10% = 1, 10–50% = 2, >50% = 3) [27]. Only posi-
tive staining in the tumor stroma was scored, and areas
with hemorrhage and necrosis were avoided. Intratumor
heterogeneity of stromal integrin α11 expression was
also noted.
As there is no pre-established cut-off value for
integrin α11, the distribution and frequency histograms
for SI were evaluated. As seen in supplementary mate-
rial, Figure S1, there was a clear binary distribution,
and the breast cancer cases were therefore separated
into integrin α11-low expression (SI 0–3 = 34%) and
integrin α11-high expression (SI 4–9 = 66%) by this
distribution, corresponding to a cut-off value at the
lower tertile.
Gene expression data sets
Gene expression microarray data generated by the
Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) were included for analyses
of ITGA11 mRNA expression across breast cancer
molecular subtypes and its relation to survival (discov-
ery and validation cohorts) [28]. Cases of the normal-
like molecular subtype were excluded, leaving n = 939
and n = 843 for analyses in the two cohorts. Two
ITGA11 probes were present in the METABRIC data.
The max probe expression value was selected for
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analyses [29]. Lower tertile was applied as cut-off,
corresponding to the cut-off level of the protein
staining.
Statistical analyses
Associations between categorical data were estimated
using the Pearson’s chi-square test and OR were com-
puted. Differences in integrin α11 protein and mRNA
expression across molecular subgroups were tested by
Kruskal–Wallis test. Results were accepted as statisti-
cally significant when p < 0.05 (two-sided). Univariate
survival data were analyzed by the Kaplan–Meier
method, with death from breast cancer as end-point
(time in months from diagnosis until death from breast
cancer), and the significance determined by the log-
rank test. Statistical analyses were performed using the
IBM SPSS Statistics for Windows, Version 25.0 (IBM
Corp, Armonk, NY, USA).
Results
Antibody specificity
As lack of reliable anti-human integrin α11 antibodies
has limited the investigation of integrin α11 on FFPE
tumor material, several novel monoclonal antibodies
specific for human integrin α11 chain were generated
and tested on FFPE tissues before use on the breast
cancer cohort. Hybridoma screening and antibody
characterization are demonstrated in [21,23], respec-
tively. In brief, clones specific to integrin α11 chain,
but not to other integrin subunits, such as integrin β1
and α2, were chosen. Furthermore, the specificity of
both 210F4B6A4 and D120.4 was validated by west-
ern blotting of cell lysates, and a polyclonal antibody
was used as control [24]. Both clone 210F4B6A4 and
D120.4 verified high expression of integrin α11 in
C2C12-α11 cells and no expression in C2C12-α2 cells
(Figure 1A). The human osteosarcoma cell line,
U2OS, showed low integrin α11 expression while the
human embryonic kidney cell line, HEK293, was neg-
ative for integrin α11 (Figure 1A). RT-qPCR con-
firmed the expression levels of integrin α11 in these
cell lines (Figure 1B).
The clones were tested on FFPE material, and it
became evident that high temperature was crucial to
unmask the antigen. Extensive testing of different pro-
tocols was done to find the most gentle antigen
retrieval protocol with high sensitivity. Several anti-
bodies showed distinct staining on FFPE tissue,
including 210F4B6A4 and D120.4. As 210F4B6A4
showed markedly strongest staining on FFPE tissue,
this antibody was used for further analyses. Staining
of FFPE cell pellets shows the validity of 210F4B6A4
on FFPE material (Figure 1C). Since other anti-
integrin α11 antibodies have been shown to lack speci-
ficity on FFPE tissue, a positive reagent control was
not applicable. Integrin α11 has recently been shown
to be highly upregulated in PDAC [21], and
corresponding cryo- and FFPE sections from the same
PDACs were used in the calibration of the IHC proto-
col, where the polyclonal integrin α11 antibody and
203E3 [21] were used as a control for the
cryosections. After optimizing the antigen retrieval
protocol on FFPE sections from cell pellets, PDACs
and invasive breast carcinomas, similar intensity and
expression pattern were seen in corresponding cryo-
and FFPE sections from five different PDACs (one
representative of five different tumors is shown in
Figure 1D). These sections were then used as biologi-
cal controls. To exclude run-to-run variability, serial
sections from five FFPE invasive breast carcinomas
were stained.
Integrin α11 is expressed in fibroblast-like cells in
breast cancer stroma
Positive staining was mainly seen as a fibrillar staining
pattern in the breast cancer stroma (Figure 2A–I and
see supplementary material, Figure S2A–I). Of note,
cells positive for integrin α11 were mainly spindle-
shaped, fibroblast-like cells, and the staining was often
markedly accentuated in direct proximity to the cancer
cells, indicating a ‘border’ between the epithelial com-
ponent and the ECM (Figure 2B,D,E,G–I and see sup-
plementary material, Figure S2A,B and D–F). In
addition to this fibrillar stromal positivity, membrane
staining of some of the breast myoepithelial cells was
also seen (Figure 3A–I).
Integrin α11 was expressed in spindle-shaped stro-
mal cells in 389 of 392 cases that were included for
evaluation (99%). The stromal staining was markedly
heterogeneous in 62% of the cases with an uneven dis-
tribution of integrin α11 expression (see supplemen-
tary material, Figure S3). Most of these heterogeneous
cases showed highest integrin α11 expression in the
central parts of the tumor with gradual loss of expres-
sion towards the invasive front (see supplementary
material, Figure S3). Integrin α11 expression was most
often weak in areas showing immune cell infiltration
(see supplementary material, Figure S2B), and fibrotic,
ECM-rich tissue was often positive for integrin α11
(see supplementary material, Figure S2C). No con-
vincing staining of tumor cells was observed, not even
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in invasive breast carcinomas with basal-like features
(see supplementary material, Figure S2G–I).
Integrin α11 co-localizes with αSMA in fibroblast-
like cells and with αSMA and cytokeratin-14 in
breast myoepithelium
To further characterize the expression of integrin
α11, we investigated its expression in relation to
αSMA, CK14, and FVIII in invasive breast carcino-
mas. Integrin α11 and αSMA expression showed a
clear co-localization in stromal spindle-shaped cells
(Figure 2D–F), but spindle-shaped cells only positive
for one of the markers were also observed (Figure 2F).
αSMA-positive, integrin α11-negative fibroblasts were
more prevalent than integrin α11-positive, αSMA-
negative fibroblasts. A minority of the vessels showed
weak integrin α11 expression.
Furthermore, integrin α11 expression was observed
in breast myoepithelial cells associated with ductal car-
cinoma in situ (DCIS), where it co-localized with
αSMA (Figure 3E–F) and CK14 (Figure 3G–I).
Integrin α11-positive myoepithelial cells were more
frequent and with higher intensity in DCIS
(Figure 3B–C,E–F, and G–I) compared to benign-
looking breast tissues where integrin α11 was mostly
negative (Figure 3D). Nevertheless, positive integrin
α11 staining was also observed in a small minority of
Figure 1. Validation of monoclonal antibodies against the integrin α11 subunit. Integrin α11-positive cell lines (C2C12-α11 and U2OS)
and integrin α11-negative cell lines (C2C12-α2 and HEK293) were used to validate the monoclonal antibodies. Western blots show only
expression of integrin α11 in cell lysates from integrin α11-positive cells using the monoclonal antibodies (mAbs) 210F4B6A4 and
D120.4 where a polyclonal antibody (pAb) was used as control (A). Comparison of mRNA expression of integrin α11 by RT-qPCR (B).
ITGA11 expression level is presented as the fold change in each cell line relative to C2C12-α11. Each column represents the average fold
change from three experiments, and error bar indicates standard deviation. Staining with 210F4B6A4 of FFPE cell pellets confirmed the
validity on FFPE material (C). Cases of pancreatic ductal adenocarcinoma stained with 210F4B6A4 showed similar stromal expression
pattern in corresponding cryosections and FFPE sections; images from one representative tumor are shown in (D). 203E3 was used as
control for the cryosections. Magnification: ×400.
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histologically benign ducts (Figure 3A). Interestingly,
Figure 2G–I and see supplementary material,
Figure S2D–F, demonstrate that the accentuated
integrin α11 expression in spindle-shaped cells near
tumor cells noted above probably represents tightly
associated fibroblasts, and not myoepithelial cells, as
these cells are negative for the myoepithelial
marker CK14.
Figure 2. Integrin α11 is expressed in fibroblast-like cells in breast cancer stroma. Integrin α11 expression in spindle-shaped cells in the
stroma of different invasive human breast carcinomas by IHC with 210F4B6A4. Different levels of integrin α11 expression are shown in
(A–C) (A; low intensity, B; medium strong intensity and C; strong intensity). (D–F) show triple staining of αSMA (yellow), integrin α11
(teal), and FVIII (purple) where co-localization of αSMA and integrin α11 appears green. Note that both integrin α11 and αSMA are
expressed in spindle-shaped stromal cells, but do not completely co-localize. Examples of double-positive spindle-shaped cells are mar-
ked with arrows, while one integrin α11-positive/αSMA-negative cell is marked with an arrowhead and one integrin α11-negative/
αSMA-positive cell marked with an asterisk. (G–I) show immunofluorescent double staining of integrin α11 (red), CK14 (green) and DAPI
(blue) of one invasive breast carcinoma. Note the strong integrin α11 expression in direct proximity to the tumor cells seen in (B), (D),
(E), and (J–L), and that this border is negative for CK14, indicating that this is not flattened integrin α11-positive breast myoepithelium.
Magnification: ×400 and ×200.
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High integrin α11 expression is associated with
features of aggressive breast cancer
Integrin α11 protein expression in stromal, spindle-
shaped cells was quantified by SI score (0–9),
obtained by multiplying the score for intensity of
staining by the score for percentage of fibrous
stroma stained. In total, 258 cases (66%) showed
high integrin α11 protein expression (SI 4–9),
whereas 134 cases (34%) showed low expression
(SI 0–3). While invasive carcinoma of no special
type, previously named invasive ductal carcinoma,
was associated with high integrin α11 protein
expression, invasive lobular carcinoma was associated
with low integrin α11 protein expression (Table 2).
Figure 3. Integrin α11 is expressed in a subgroup of breast myoepithelial cells. (A–C) show single staining of integrin α11 with weak
myoepithelial integrin α11 expression in benign-appearing ducts (A) and high myoepithelial integrin α11 expression in DCIS lesions
(B and C). (D–F) show triple staining of αSMA (yellow), integrin α11 (teal), and FVIII (purple) where co-localization of αSMA and integrin
α11 appears green; (D) shows terminal ducts and lobular units outside an invasive breast carcinoma with αSMA-positive, integrin
α11-negative myoepithelial cells, while (E–F) show co-localization of myoepithelial integrin α11 and αSMA in DCIS lesions. (G–I) shows
immunofluorescent double staining of integrin α11 (red), CK14 (green) and DAPI (blue) of one DCIS lesion with co-localization of
integrin α11 and CK14 in myoepithelial cells. IHC with 210F4B6A4. Magnification: ×400 and ×200.
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Furthermore, the expression of integrin α11 was sig-
nificantly higher in the aggressive HER2-positive
breast cancer subgroup both at protein and mRNA
level (Figures 4A and 5A,C).
Using the lower tertile as cut-off value (SI 0–3 =
34% versus SI 4–9 = 66%), high integrin α11 protein
expression was significantly associated with high histo-
logic grade (OR 5.0), estrogen receptor (ER) negativity
(OR 2.9), HER2 positivity (OR 2.7), triple-negative
phenotype (OR 2.5) and high tumor cell proliferation
by Ki-67 (OR 2.9) and mitotic count (OR 4.5)
(Table 2). Furthermore, high integrin α11 protein
expression was associated with the basal cell marker
CK5/6 (OR 3.3), but not with tumor diameter or lymph
node metastasis (Table 2).
In univariate survival analyses, neither integrin α11
protein expression nor integrin α11 mRNA expression
were significantly associated with breast cancer spe-
cific survival (Figures 4B and 5B,D). No significant
associations between integrin α11 expression and
breast cancer specific survival were found across dif-
ferent molecular breast cancer subgroups (see supple-
mentary material, Figures S4–S6), except that high
integrin α11 mRNA expression was found to be asso-
ciated with reduced survival in the Luminal B sub-
group in the METABRIC discovery cohort (see
Table 2. Associations between integrin α11 protein expression and clinico-pathological variables
α11 low (n = 134) α11 high (n = 258)
Variables n (%) n (%) OR (95% CI) P value*
Ductal carcinoma <0.001
No 37 (58) 27 (42) 1
Yes 97 (30) 231 (70) 3.3 (1.9–5.7)
Lobular carcinoma <0.001
Yes 27 (67) 13 (33) 1
No 107 (30) 245 (70) 4.8 (2.4–9.6)
Histologic grade <0.001
Grade 1–2 125 (40) 190 (60) 1
Grade 3 9 (12) 68 (88) 5.0 (2.4–10.3)
Tumor diameter 0.96
≤2 cm 98 (34) 188 (66) 1
>2 cm 36 (34) 70 (66) 1.0 (0.6–1.6)
Mitotic count†,‡ <0.001
Low count (≤5.5/mm2) 117 (43) 158 (57) 1
High count (>5.5/mm2) 16 (14) 98 (86) 4.5 (2.5–8.1)
Lymph node status 0.11
Negative 101 (37) 175 (63.4) 1
Positive 32 (28) 82 (72) 1.5 (0.9–2.4)
ER 0.001
Positive (≥10%) 121 (38) 197 (62) 1
Negative (<10%) 13 (18) 61 (82) 2.9 (1.5–5.5)
PR 0.53
Positive (≥10%) 91 (35) 167 (65) 1
Negative (<10%) 43 (32) 91 (68) 1.2 (0.7–1.8)
HER2§ 0.004
Negative 123 (37) 209 (63) 1
Positive 10 (18) 47 (82) 2.7 (1.3–5.7)
Ki67† <0.001
Low count (≤31.5%) 111 (41) 163 (59) 1
High count (>31.5%) 22 (19) 93 (81) 2.9 (1.7–4.9)
Triple-negative 0.022
No 126 (36) 223 (64) 1
Yes 8 (19) 35 (81) 2.5 (1.1–5.5)
CK 5/6 0.001
Negative (SI = 0) 124 (38) 207 (62) 1
Positive (SI > 0) 9 (16) 49 (84) 3.3 (1.5–6.9)
n, number of patients; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CK 5/6, cytokeratin 5/6; SI: staining
index.
*Pearson chi-square.
†Cut-off value by upper quartile.
‡Mitotic count: number of mitoses per mm2.
§HER2-positive cases: HER2 IHC3+ and HER2 IHC2+ cases with a HER2/Chr17 ratio by silver in situ hybridization ≥ 2.0.
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Figure 4. Integrin α11 protein expression in human breast cancer. Integrin α11 protein expression across molecular subtypes of breast
cancer; data are presented as error-bars with 95% confidence interval of the mean, and P values by the Kruskal–Wallis test (A). Survival
curve by the Kaplan–Meier method for stromal integrin α11 expression; breast cancer specific survival in months, and P value by log-
rank test (B). For each category, the number of breast cancer deaths is given, followed by the total number of cases in each category.
Figure 5. Integrin α11 mRNA expression in human breast cancer in the METABRIC discovery and validation datasets. Integrin α11 mRNA
expression across molecular subtypes of breast cancer; data are presented as error-bars with 95% confidence interval of the mean, and
P values by the Kruskal–Wallis test (A,C). Survival curves by the Kaplan–Meier method for integrin α11 mRNA expression; breast cancer
specific survival in years, and P value by log rank test (B,D). For each category, the number of breast cancer deaths is given, followed by
the total number of cases in each category.
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supplementary material, Figure S5B), but this was not
validated at the protein level or in the METABRIC
validation cohort (see supplementary material, Fig-
ures S4B,C and S6B).
Discussion
Integrin α11β1 has been shown experimentally to stimu-
late tumor growth and progression [16,17,19,20], and to
be essential for fibroblast-matrix interactions [5,30].
Here, we present two new monoclonal mouse anti-
human integrin α11 antibodies, 210F4B6A4 and
D120.4, which bind to extracellular and intracellular
epitopes of the integrin α11 subunit, respectively. We
have established conditions for specific and reproduc-
ible integrin α11 staining of human FFPE tumor
material with 210F4B6A4. In a large breast cancer
cohort with long and complete follow-up, integrin
α11 was found to be expressed to varying degrees in
the stroma of 99% of the cases. In agreement with a
tumor-supportive effect of integrin α11β1, high
integrin α11 expression was associated with more
aggressive breast cancer phenotypes, even though
integrin α11 expression was not significantly corre-
lated to breast cancer specific survival.
Since existing anti-integrin α11 antibodies have
been shown to lack specificity on FFPE material in
our laboratory, we carefully developed and character-
ized novel antibodies. Since integrin α2 is one of the
most similar integrin chains [24], and is also found
expressed on fibroblasts [5], extra efforts were made
to exclude cross-reactivity against this integrin subunit.
The new monoclonal antibody 210F4B6A4 described
herein binds specifically to the integrin α11-chain
under several conditions, including western blotting
and immunostaining of FFPE material.
Although experimental studies have indicated a
tumor-stimulating effect of integrin α11β1 in different
preclinical models [16,17,19,20], and integrin α11β1
therefore has been suggested as a potential marker of a
pro-tumorigenic CAF subset, few investigations have
been performed on human tumor tissue due to lack of
a reliable antibody for use on FFPE material. In the
present study, investigating a breast cancer cohort of
392 patients, high integrin α11 expression in stromal
spindle-shaped cells was significantly associated with
high histologic grade, HER2 positivity, ER negativity,
triple-negative phenotype and expression of the basal
cell marker CK5/6, as well as high tumor cell prolifer-
ation by Ki-67 expression and mitotic count - all
markers of aggressive breast cancer phenotypes.
Notably, integrin α11 was expressed at higher protein
and mRNA levels in the aggressive HER2-positive
subtype of breast cancer. In addition to existing pre-
clinical data, these findings may indicate that integrin
α11-positive fibroblasts represent a subset of tumor-
supportive breast CAFs. However, high integrin α11
protein and mRNA expression was not associated with
survival. Similarly, Parajuli et al [31] did not find cor-
relations between stromal integrin α11 expression and
patient outcome in a series of head and neck cancers
using cryosections from the tumor center.
The cellular expression of different integrins is not
only subtype-specific, but is also dependent on tissue
type and context [4,32,33]. In the case of integrin
α11β1, the expression appears to be restricted to a
subgroup of fibroblasts and mesenchymal stem cells
[5], but the characterization of expression in human
tissue is so far limited. As there is a need to better
characterize CAF heterogeneity and to identify
markers that can help distinguish between tumor-
supportive and tumor-suppressive CAFs, several
IHC-based studies have used different markers to
identify tumor-supportive breast CAFs, such as
αSMA [34,35] and PDGFRβ [36,37]. In the present
study, we found that the integrin α11 subunit was
expressed in fibroblast-like cells in the breast tumor
stroma, and it predominantly co-localized with
αSMA. Similarly, αSMA and integrin α11 have pre-
viously been found to co-localize in the tumor stroma
of human head and neck cancers [31]. However, stro-
mal spindle-shaped cells with expression of either
integrin α11 or αSMA only were also observed in the
present study, which may represent different subpop-
ulations of CAFs (α11+/αSMA+, α11+/αSMA−, and
α11−/αSMA+) with potential functional differences
which should be investigated in future studies.
Normal mammary epithelium consists of an inner
luminal and a surrounding myoepithelial cell layer
[38]. Interestingly, integrin α11 was also found to
be expressed on myoepithelial cells surrounding
DCIS lesions, where it was found to co-localize
with αSMA and CK14, common markers of breast
myoepithelium. While αSMA and CK14 are general
myoepithelial markers, integrin α11 myoepithelial
expression appears to be more restricted, and was
mainly detected in in situ lesions, with absent or
very weak expression in benign-appearing lobules
and ducts. While the myoepithelium of benign ducts
is thought to act as an active tumor suppressor,
accumulating data indicate that DCIS-associated
myoepithelial cells show genetic, epigenetic and
molecular changes compared to myoepithelium in
benign tissue, and that their tumor-suppressive
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function may be lost with DCIS progression
[39,40]. As changes in myoepithelial cells have
been suggested to be an important contribution in
the transition from preinvasive to invasive cancer,
the molecular differences in preinvasive lesions may
represent markers for risk stratification or even tar-
gets for prevention of invasive breast cancer. Inter-
estingly, upregulation of another integrin, integrin
αvβ6, in breast myoepithelium, has been associated
with poor patient outcome and shown to promote
breast tumor proliferation experimentally [41].
Additional studies should address the role of myo-
epithelial integrin α11 expression in DCIS cohorts.
We observed fibrillar integrin α11 positivity which
was clearly strongest in direct proximity to the tumor
cells in the majority of breast cancer samples, and
dual staining with CK14 demonstrated that these cells
are probably not flattened myoepithelial cells. By the
methods used in this study, we cannot exclude that
such accentuated integrin α11 staining adjacent to
cancer cells may represent a subset of the tumor cell
population with a mesenchymal phenotype. Indeed,
integrin α11β1 has been suggested to be upregulated
during epithelial-to-mesenchymal transition, as it was
found to be part of a gene signature for some invad-
ing breast cancer cells in vitro [42], although this has
not been confirmed in other models or at the protein
level.
In conclusion, we have shown that the integrin
α11 subunit is expressed in fibroblasts-like cells in
invasive human breast carcinomas, and in myo-
epithelial cells in in situ lesions. High stromal
integrin α11 expression was associated with aggres-
sive breast cancer phenotypes, although integrin α11
mRNA and protein expression did not correlate with
breast cancer specific survival. It will be of further
interest to examine the expression of integrin α11 in
relation to other CAF markers, and to study the
functional role of integrin α11-expressing subpopu-
lations of breast CAFs.
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